BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22554523)

  • 21. The pleiotropic profile of the indirubin derivative 6BIO overcomes TRAIL resistance in cancer.
    Braig S; Bischoff F; Abhari BA; Meijer L; Fulda S; Skaltsounis L; Vollmar AM
    Biochem Pharmacol; 2014 Sep; 91(2):157-67. PubMed ID: 25069048
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-gout agent allopurinol exerts cytotoxicity to human hormone-refractory prostate cancer cells in combination with tumor necrosis factor-related apoptosis-inducing ligand.
    Yasuda T; Yoshida T; Goda AE; Horinaka M; Yano K; Shiraishi T; Wakada M; Mizutani Y; Miki T; Sakai T
    Mol Cancer Res; 2008 Dec; 6(12):1852-60. PubMed ID: 19074830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis.
    Rachner TD; Benad P; Rauner M; Goettsch C; Singh SK; Schoppet M; Hofbauer LC
    J Cell Biochem; 2009 Sep; 108(1):106-16. PubMed ID: 19544400
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Triptolide sensitizes resistant cholangiocarcinoma cells to TRAIL-induced apoptosis.
    Panichakul T; Intachote P; Wongkajorsilp A; Sripa B; Sirisinha S
    Anticancer Res; 2006; 26(1A):259-65. PubMed ID: 16475706
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CGP74514A enhances TRAIL-induced apoptosis in breast cancer cells by reducing X-linked inhibitor of apoptosis protein.
    Park S; Shim SM; Nam SH; Andera L; Suh N; Kim I
    Anticancer Res; 2014 Jul; 34(7):3557-62. PubMed ID: 24982369
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aspirin enhances TRAIL-induced apoptosis via regulation of ERK1/2 activation in human cervical cancer cells.
    Im SR; Jang YJ
    Biochem Biophys Res Commun; 2012 Jul; 424(1):65-70. PubMed ID: 22728039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction.
    Schulze-Bergkamen H; Fleischer B; Schuchmann M; Weber A; Weinmann A; Krammer PH; Galle PR
    BMC Cancer; 2006 Oct; 6():232. PubMed ID: 17014711
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hispidulin sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by AMPK activation leading to Mcl-1 block in translation.
    Yang JM; Hung CM; Fu CN; Lee JC; Huang CH; Yang MH; Lin CL; Kao JY; Way TD
    J Agric Food Chem; 2010 Sep; 58(18):10020-6. PubMed ID: 20734985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mcl-1: a gateway to TRAIL sensitization.
    Kim SH; Ricci MS; El-Deiry WS
    Cancer Res; 2008 Apr; 68(7):2062-4. PubMed ID: 18381408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Down-regulation of RIP1 by 2-deoxy-D-glucose sensitizes breast cancer cells to TRAIL-induced apoptosis.
    Huang YY; Liu H; Li Y; Pu LJ; Jiang CC; Xu JC; Jiang ZW
    Eur J Pharmacol; 2013 Apr; 705(1-3):26-34. PubMed ID: 23499682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells.
    Matsuzaki H; Schmied BM; Ulrich A; Standop J; Schneider MB; Batra SK; Picha KS; Pour PM
    Clin Cancer Res; 2001 Feb; 7(2):407-14. PubMed ID: 11234897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase.
    Nakshatri H; Rice SE; Bhat-Nakshatri P
    Oncogene; 2004 Sep; 23(44):7330-44. PubMed ID: 15286701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP.
    Kang J; Bu J; Hao Y; Chen F
    Prostate Cancer Prostatic Dis; 2005; 8(3):274-9. PubMed ID: 15897917
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Programmed cell death 4 (PDCD4) mediates the sensitivity of gastric cancer cells to TRAIL-induced apoptosis by down-regulation of FLIP expression.
    Wang W; Zhao J; Wang H; Sun Y; Peng Z; Zhou G; Fan L; Wang X; Yang S; Wang R; Fang D
    Exp Cell Res; 2010 Sep; 316(15):2456-64. PubMed ID: 20595005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anisomycin treatment enhances TRAIL-mediated apoptosis in renal carcinoma cells through the down-regulation of Bcl-2, c-FLIP(L) and Mcl-1.
    Seo BR; Min KJ; Kim S; Park JW; Park WK; Lee TJ; Kwon TK
    Biochimie; 2013 Apr; 95(4):858-65. PubMed ID: 23261849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The coffee diterpene kahweol sensitizes TRAIL-induced apoptosis in renal carcinoma Caki cells through down-regulation of Bcl-2 and c-FLIP.
    Um HJ; Oh JH; Kim YN; Choi YH; Kim SH; Park JW; Kwon TK
    Chem Biol Interact; 2010 Jun; 186(1):36-42. PubMed ID: 20403343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL.
    El Fajoui Z; Toscano F; Jacquemin G; Abello J; Scoazec JY; Micheau O; Saurin JC
    Gastroenterology; 2011 Aug; 141(2):663-73. PubMed ID: 21683075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model.
    Thai le M; Labrinidis A; Hay S; Liapis V; Bouralexis S; Welldon K; Coventry BJ; Findlay DM; Evdokiou A
    Cancer Res; 2006 May; 66(10):5363-70. PubMed ID: 16707463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma.
    Ndozangue-Touriguine O; Sebbagh M; Mérino D; Micheau O; Bertoglio J; Bréard J
    Oncogene; 2008 Oct; 27(46):6012-22. PubMed ID: 18560353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chetomin induces degradation of XIAP and enhances TRAIL sensitivity in urogenital cancer cells.
    Yano K; Horinaka M; Yoshida T; Yasuda T; Taniguchi H; Goda AE; Wakada M; Yoshikawa S; Nakamura T; Kawauchi A; Miki T; Sakai T
    Int J Oncol; 2011 Feb; 38(2):365-74. PubMed ID: 21165560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.